Other Headlines

Advocacy groups applaud passage of bill that would permanently repeal and replace SGR.
The medical community pays tribute to a dedicated crew.
A novel microfluidic drug delivery system makes it possible to reach parts of the body poorly served by oral and injectable medications.
Thanks to a European grant for the HyperIMAGE project, a consortium of scientists across Europe have worked with Philips to develop a proof-of-concept, pre-clinical combined MR-PET scanner that could one day lead to improved radiation therapy and cardiology treatments.
The "germ theory" of schizophrenia got a mild boost this week as scientists discover that recently afflicted schizophrenics show higher levels of inflammatory proteins in the brain.

Have News for Us?

Submit your news on the industry, people, or companies.

Forward to a Friend

More Industry Headlines

House Passes Medicare Physician Payment Reform Act Advocacy groups applaud passage of bill that would permanently repeal and replace SGR.

Aural Trumps Oral for Ear Treatment A novel microfluidic drug delivery system makes it possible to reach parts of the body poorly served by oral and injectable medications.

Clinical PET-MRI Moves Closer to Reality Thanks to a European grant for the HyperIMAGE project, a consortium of scientists across Europe have worked with Philips to develop a proof-of-concept, pre-clinical combined MR-PET scanner that could one day lead to improved radiation therapy and cardiology treatments.

Scientists Find Unusual Immune System Activity in Brains of Schizophrenics The "germ theory" of schizophrenia got a mild boost this week as scientists discover that recently afflicted schizophrenics show higher levels of inflammatory proteins in the brain.

Senate Health Care Reform Bill Unveiled Legislation may go to cloture vote this weekend. Read the details.

RSNA 2009 Preview This year's RSNA should provide a very interesting look at the effects of the economy on the major OEMs. As always, vendors are whipping up the hoopla, and inside this story are great previews of what's being debuted. But DOTmed reporters will also be there to get the real buzz. Look for video interviews in our Online News direct from the show.

Interview With Fred Robertson, President & CEO of TomoTherapy TomoTherapy president and CEO Fred Robertson talks with DOTmed about his perspective on ASTRO's 2009 annual meeting, changes in the radiation oncology industry and two important TomoTherapy product launches that occurred at the show. Watch the HD video.

Pen-Sized Microscope Aims for Precise Brain Surgeries A confocal microscope picking up brain-safe fluorescent dyes could result in more accurate and streamlined surgeries to remove tumors from the brain.

Health Care Reform Round-Up: CBO Pegs Senate Bill at $849 Billion The numbers are in on the Senate's version of reform. Also read about the wide-ranging impact that the legislation would have.

U.S. Preventive Services Task Force Has Stunning New Guidelines on Mammography Agency recommends no routine screening for women 40-49, no self-examination. Read the details.

The company is
complying appropriately
with the DOJ request

Medtronic Receives Subpoena From U.S. Justice Department

November 24, 2008
by Joan Trombetti, Writer
A subpoena has been sent to Medtronic Inc., as part of an investigation into unapproved "off-label," uses of Infuse spinal graft. Bill Hawkins, Chief Executive for the Minneapolis-based Medtronic responded to the subpoena by saying that for years the company has had strict guidelines in place on appropriate promotion of products according to labeled indications and the company is complying appropriately with the DOJ's request.

He also said that the investigation was "very focused" on Infuse, and he didn't know if it would be broadened. It was not a surprise to Hawkins that Medtronic, the world's largest medical device maker received the subpoena on the subject, given "stepped-up efforts in general on the topic of off-label use of drugs and devices."

Doctors are free to prescribe drugs for uses not approved by federal regulators or to use devices as they see fit. But pharmaceutical and medical device companies are prohibited by law from marketing for those uses.

Medtronic has said it does not pay surgeons to promote Infuse for unapproved uses. Company spokesman Chuck Grothaus reaffirmed that but said Medtronic would not elaborate on the subpoena.

In 2006 Medtronic reached a $40 million settlement with the U.S. Department of Justice to settle charges that it paid physicians millions in kickbacks to use its spinal repair products. Medtronic denied any wrongdoing.

As part of the arrangement, the government agreed to seek dismissal of the two cases brought by former employees in U.S. District Court in Memphis, where the company's spinal division has offices.

The Infuse graft uses a man-made version of a human protein to encourage bone growth. The Food and Drug Administration approved the system to fuse parts of the spine together during lower-back surgery as well as for oral and dental procedures.

However, serious complications have been reported when the graft is used for alternate uses. In July the FDA warned doctors that use of Infuse for neck surgeries has led to problems swallowing, breathing and speaking, which in some cases required additional surgeries.


Interested in Medical Industry News? Subscribe to DOTmed's weekly news email and always be informed. Click here, it takes just 30 seconds.

Please Send us your Comments.

Printable Story
Access and use of this site is subject to the terms and conditions of our LEGAL NOTICE & PRIVACY NOTICE
Property of and Proprietary to DOTmed.com, Inc. Copyright ©2001-2009 DOTmed.com, Inc.
ALL RIGHTS RESERVED